Notably, combining checkpoint inhibitors with patient stratification has led to the approval of Pembrolizumab (an anti-PD-1 monoclonal antibody) in previously untreated NSCLC patients with PD-L1 positive tumors [14]. Here, CD274 is linked to non-small cell lung carcinoma.